Overview of the CLL2-BIG trial of ibrutinib and obinutuzumab
Julia von Tresckow
Obinutuzumab and venetoclax for high-risk CLL: upcoming CLL14 trial
What is the role for idelalisib and duvelisib in CLL?
A new prognostic tool for CLL: CLL-IPI
Combining targeted agents with checkpoint inhibitors in cutaneous T-cell lymphoma